Program

Program Wednesday, 2 November 2016

7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Hall F2 (L0)
VALUE OPTIMIZATION IN HCV: BEYOND HEALTH ECONOMICS

(Sponsored by AbbVie)

8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Hall F1 (L0)

IP14: EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES?

Moderator:

Rok Hren, PhD, MSc IHP(HE), Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

Panelists:

Tomas Tesar, PharmD, PhD, MBA, Member of the Reimbursement Committee of the Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovakia

Andras Inotai, PharmD, PhD, Senior Pharmacoeconomist, Syreon Research Institute, Budapest, Hungary

Duša Hlade Zore, MD, Representative of Patients’ Rights, Ministry of Health, Government of the Republic of Slovenia, Ljubljana, Slovenia


8:45 - 9:45
Room: Hall E1 (L0)

IP15: IS BALANCING VALUE DEMONSTRATION FOR PAYER AND PATIENT INTERESTS A FEASIBLE NOTION?

Moderator:

Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA

Panelists:

Sachin Kamal-Bahl, PhD, Vice President & Head, Global Health & Value Innovation Center, Pfizer, Collegeville, PA, USA

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK


8:45 - 9:45
Room: Hall E2 (L0)
W22: VALUE OF INFORMATION ANALYSIS TO SUPPORT COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEMES: INDUSTRY VERSUS PAYER PERSPECTIVE
Discussion Leaders:

Leyla Mohseninejad, MSc, PhD, HEOR Manager, Creativ-Ceutical, Rotterdam, The Netherlands

Saskia Knies, PhD, Policy Advisor Health Economics, National Health Care Institute (ZiN), Diemen, The Netherlands

Mondher Toumi, MD, PhD, MSc, Professor, Public Health Department, Aix-Marseille University, Marseille, France


8:45 - 9:45
Room: Hall A (L2)
W23: ALL MODELS ARE WRONG, BUT SOME ARE LESS WRONG: USING A VERIFICATION PROTOCOL TO FIND THESE LESS WRONG ONES ON THE MODEL FARM?
Discussion Leaders:

Maiwenn J. Al, PhD, Assistant Professor, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

Nasuh Buyukkaramikli, PhD, Senior Researcher, Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands

Rachid Rafia, PhD, Senior Researcher, Sheffield University, Sheffield, UK

Dawn Lee, MMath, MSc, Head of Health Economics Analysis, BresMed Health Solutions, Sheffield, UK


8:45 - 9:45
Room: Hall F2 (L0)
W24: ADAPTING TO EVOLVING EVIDENCE REQUIREMENTS IN GLOBAL MEDICAL DEVICE DEVELOPMENT PROGRAMS
Discussion Leaders:

Thomas Goss, PharmD, Sr. Vice President, Boston Healthcare Associates, Boston, MA, USA

Mark Campbell, MPhil, Associate Director - Medical Technologies Evaluation Programme, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, UK, Manchester, UK

Pascale Brasseur, MSc, BSc, Global Health Economics & Reimbursement Director, Spine & Biologics, Medtronic plc, Tolochenaz, Switzerland

Moore Matt, MHA, Director, Global Health Economics and Reimbursement, Edwards Lifesciences, Irvine, CA, USA

8:45 - 13:45
RESEARCH POSTER PRESENTATIONS - SESSION V
9:45 - 10:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
10:00 - 11:00
BREAKOUT SESSION

10:00 - 11:00
Room: Hall E1 (L0)

IP16: SHOULD HEALTH TECHNOLOGY ASSESSMENT GUIDELINES RECOMMEND INCLUSION OF FUTURE MEDICAL COSTS?

Moderator:

Andrew Briggs, DPhil, MSc, William R Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK

Panelists:

Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK

Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management (iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands

Ad Antonisse, MSc, Director Economic Affairs (Market Access & Public Affairs), AstraZeneca, Zoetermeer, The Netherlands


10:00 - 11:00
Room: Hall A (L2)

IP17: CAN WE REALLY COMPARE AND AGGREGATE PATIENT-REPORTED OUTCOME DATA BETWEEN PEOPLE AND SETTINGS? IMPLICATIONS FOR CLINICAL TRIALS AND HEALTH TECHNOLOGY ASSESSMENT

Moderator:

Nancy Devlin, PhD, Director of Research, Office of Health Economics, London, UK

Panelists:

Michael Herdman, MSc, Director, Insight Consulting and Research, Mataró, Spain

Paula Lorgelly, PhD, Deputy Director, Office of Health Economics, London, UK

Andrea Manca, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK


10:00 - 11:00
Room: Hall E2 (L0)
W25: SPHERE OF INFLUENCE: RUSSIA'S EMERGING HEALTH TECHNOLOGY ASSESSMENT AND ITS INFLUENCE OVER ACCESS IN CIS COUNTRIES
Discussion Leaders:

Cyrus A. Chowdhury, CEO & Managing Director, CBPartners, New York, NY, USA

Malwina Holownia, MPharm, Senior Health Economist, Moscow Department of Health, Moscow, Russian Federation

Elena Subbotina, MIM, MSc, Consultant, CBPartners, London, UK


10:00 - 11:00
Room: Hall F1 (L0)
W26: BIOSIMILAR VALUE GENERATION OR VALUE DESTRUCTION? A WORKSHOP DEMONSTRATING UPTAKE TO DATE AND QUANTIFYING SAVINGS MADE
Discussion Leaders:

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Monique Martin, PharmD, MSc, MBA, Managing Director PMA Europe, inVentiv Health, London, UK


10:00 - 11:00
Room: Hall F2 (L0)
W27: GUIDELINES FOR ANALYZING PUBLISHED SUMMARY TIME TO EVENT DATA
Discussion Leaders:

Jack Ishak, PhD, Senior Research Leader, Modeling and Simulation, Evidera, Montreal, QC, Canada

Martin Hoyle, PhD, Associate Professor of Health Economics, Medical School, University of Exeter, Exeter, UK

Arman Altincatal, MS, Senior Statistician, Evidera, Lexington, MA, USA

11:15 - 12:45
WELCOME & THIRD PLENARY SESSION
Room: Hall A (L2)
WELCOME FROM ISPOR PRESIDENT
Lou Garrison, PhD bio
2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Room: Hall A (L2)
ISPOR SERVICE AWARDS
Lou Garrison, PhD bio
2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Room: Hall A (L2)
CONGRESS RESEARCH PRESENTATION AWARDS
Paolo A. Cortesi, PhD
Researcher, Research Centre on Public Health, University of Milano - Bicocca, Milan, Italy
Ursula Rochau, MSc
Assistant Professor, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT, Hall i.T, Tirol, Austria
Room: Hall A (L2)
ISPOR 20TH ANNUAL EUROPEAN CONGRESS ANNOUNCEMENT
Lou Garrison, PhD bio
2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Room: Hall A (L2)
THIRD PLENARY SESSION: HOW TO CONTROL COSTS AND IMPROVE ACCESS TO MEDICINES: LESSONS FROM THE INTERQUALITY PROJECT
This session will describe a number of important themes emerging from the InterQuality Project.  One key finding was the importance of equity of access to health services and medicines. For example, the proportion of households with “catastrophic” out-of-pocket health spending in Poland was much higher than in either Denmark or Germany, and concentrated in the worst-off groups of senior citizens.  The new Minister of Health launched a program of free medicines for senior citizens of Poland.  A second important theme was how evidence on patients’ preferences can be integrated into health technology assessment (HTA) using efficiency frontier concept to identify the most efficient strategy within a disease class in regulatory decision-making in Germany.  Finally, while most European Union (EU) member states promote the implementation of innovative analytical methods or e-health tools, such as e-prescribing, these efforts are not part of an integrated package. Currently, no single agent manages insured patients’ access to medicines and healthcare in a coordinated manner.  More attention should be paid by EU member states to an institutional framework integrating the various methods and e-health tools to enhance benefits to both individuals and societies.
Moderator: Tomasz Hermanowski, PhD
InterQuality Project Leader and Professor & Head, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
Speaker: Anna Zawada, MSc
Director, Transparency and Tariff Councils Office, Agency for Health Technology Assessment and Tariff System (AOTMiT), Warsaw, Poland
Speaker: Joanna Lis, MSc, MBA, PhD
Director, Market Access, Sanofi-Aventis, Warsaw, Poland
Speaker: Axel Muehlbacher, PhD
Professor, Neubrandenburg University, Neubrandenburg, Germany
Speaker: Brian K. Solow, MD, FAAFP
Chief Medical Officer, Optum Life Sciences, Irvine, CA, USA
12:45 - 13:45
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
12:45 - 13:45
POSTER AUTHOR DISCUSSION HOUR - SESSION V
13:45 - 14:45
BREAKOUT SESSION

13:45 - 14:45
Room: Hall E1 (L0)

IP18: PATIENT PREFERENCES IN DRUG EVALUATION: WHICH METHOD SHOULD WE USE?

Moderator:

Heather L. Gelhorn, PhD, Senior Research Scientist, Outcomes Research, Evidera, Bethesda, MD, USA

Panelists:

Tommi Tervonen, PhD, Senior Research Associate, Evidera Ltd, London, UK

Axel C. Mühlbacher, PhD, MBA, Professor, Health Economics and Health Care Management, Institute Health Economics and Health Care Management, IGM, Hochschule Neubrandenburg, Neubrandenburg, Germany

Douwe Postmus, PhD, Researcher, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands


13:45 - 14:45
Room: Hall A (L2)

IP19: USING OBSERVATIONAL (‘REAL WORLD’) DATA IN HEALTH TECHNOLOGY ASSESSMENT: ROUTE TO CONFUSION OR BETTER DECISIONS?

Moderator:

Sarah Garner, PhD, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK

Panelists:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics & Director, Programme on Economic Evaluation and Health Technology Assessment, University of York, Heslington, York, UK

Keith R Abrams, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK

Michael Seewald, PhD, Global Head Real World Evidence, Novartis, Basel, Germany


13:45 - 14:45
Room: Hall E2 (L0)
W28: HEALTH-ECONOMIC EVALUATION OF GENOMIC TECHNOLOGIES: WHICH ISSUES ARISE?
Discussion Leaders:

Kjm van Nimwegen, MSc, PhD Student, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands

Rene Sluiter, MSc, PhD Student, Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands

Gerardus WJ Frederix, PhD, Post-doc, Julius Centre, Utrecht University, Utrecht, The Netherlands

Sarah Wordsworth, PhD, Associate Professor, Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK


13:45 - 14:45
Room: Hall F1 (L0)
W29: TRANSLATING VALUE OVER THE LIFECYCLE OF A THERAPY: DEVELOPING EVIDENCE ACROSS MULTIPLE INDICATIONS
Discussion Leaders:

Caroline Solon, MSc, Senior Associate, CBPartners, San Francisco, CA, USA

Meghan Gallagher, Director, Global Health Economics and Outcomes Research, Oncology, Sanofi, Cambridge, MA, USA

Cyrus A. Chowdhury, CEO & Managing Director, CBPartners, New York, NY, USA


13:45 - 14:45
Room: Hall F2 (L0)
W30: MEASURING MULTIPLE MEDICATION ADHERENCE – WHICH MEASURE WHEN?
Discussion Leaders:

Priti Pednekar, MPharm, PhD Student, Health Policy, University of the Sciences, Philadelphia, PA, USA

Tamas Agh, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary

Maria Malmenäs, MSc, Director Hemu, HERON Commercialization, PAREXEL International, Stockholm, Sweden

Bryan Bennett, PhD, Director, Patient Centered Outcomes, Adelphi Values Ltd, Bollington, UK

14:45 - 15:00
BREAK
15:00 - 16:00
BREAKOUT SESSION

15:00 - 16:00
Room: Hall F2 (L0)

IP20: IS REAL-WORLD DATA AS AN INDISPENSABLE SOURCE FOR THE ASSESSMENT OF NEW ONCOLOGY TREATMENTS POSSIBLE?

Moderator:

Stefano Capri, PhD, Adjunct Professor, School of Economics and Management, LIUC University, Castellanza VA, Italy

Panelists:

David Chao, BMBCh, FRCP, DPhil, Consultant in Medical Oncology, Royal Free Hospital, London, UK

Ken Redekop, PhD, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands


15:00 - 16:00
Room: Hall E1 (L0)

IP21: IS OFF-LABEL DRUG USE ENHANCING OR LIMITING ACCESS FOR PATIENTS WITH RARE DISEASES?

Moderator:

Annabel Griffiths, PhD, Consultant, Costello Medical Consulting Ltd, Cambridge, UK

Panelists:

Jack Scannell, DPhil, Co-head European Pharmaceuticals, UBS Investment Bank, London, UK

Oliver Timmis, MA, CEO, AKU Society, Cambridge, UK

Pilar Pinilla-Dominguez, MSc, Technical Adviser, NICE Scientific Advice, National Institute for Health and Care Excellence, London, UK


15:00 - 16:00
Room: Hall E2 (L0)
W31: DETERMINING UTILITY OF MULTI-ATTRIBUTE HEALTH STATES: NEW MEASUREMENT AND ANALYTIC APPROACHES
Discussion Leaders:

Nan Luo, PhD, Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

Kim Rand-Hendriksen, PhD, CPsychol, Post-Doctoral Fellow, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

Mark Oppe, PhD, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands

Juan Manuel Ramos Goñi, MSc, Senior Researcher, EuroQol Research Foundation, Rotterdam, The Netherlands


15:00 - 16:00
Room: Hall F1 (L0)
W32: HOW TO INCORPORATE ECONOMIC EVALUATIONS IN CLINICAL PRACTICE GUIDELINES: A PRACTICAL WORKSHOP ON RESEARCH METHODS
Discussion Leaders:

Jos Kleijnen, MD, PhD, Professor, Kleijnen Systematic Reviews Ltd., York, UK

Ghislaine APG van Mastrigt, PhD, Senior HTA Researcher, Department of Health Services Research, Maastricht University, Maastricht, The Netherlands

Ben Wijnen, MSc, HTA researcher, Department of Health Services Research, Maastricht University, Maastricht, The Netherlands

Frederick Thielen, Msc, HTA Researcher, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands


Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.